Reimbursing Rare Disease Drugs: Getting Away From High Co-Pays
This article was originally published in RPM Report
Executive Summary
Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.